Analysts tout Akero's data as potentially the best for MASH ...

Moomoo AI Mar 5, 2024 01:06

Analysts tout Akero's data as potentially the best for MASH treatment. Jefferies' Michael Yee labels it as 'best-in-class and best-in-disease therapeutic', while Cantor Fitzgerald's Prakhar Agrawal believes it dispels concerns about competition from drugs like Lilly's tirzepatide.

Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market -- Barrons.com

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

21K Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4899

Followers

Following

11K

Visitors